Your browser doesn't support javascript.
loading
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
Brown, Fiona C; Cifani, Paolo; Drill, Esther; He, Jie; Still, Eric; Zhong, Shan; Balasubramanian, Sohail; Pavlick, Dean; Yilmazel, Bahar; Knapp, Kristina M; Alonzo, Todd A; Meshinchi, Soheil; Stone, Richard M; Kornblau, Steven M; Marcucci, Guido; Gamis, Alan S; Byrd, John C; Gonen, Mithat; Levine, Ross L; Kentsis, Alex.
Affiliation
  • Brown FC; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cifani P; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Drill E; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • He J; Foundation Medicine, Cambridge, MA, USA.
  • Still E; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhong S; Foundation Medicine, Cambridge, MA, USA.
  • Balasubramanian S; Foundation Medicine, Cambridge, MA, USA.
  • Pavlick D; Foundation Medicine, Cambridge, MA, USA.
  • Yilmazel B; Foundation Medicine, Cambridge, MA, USA.
  • Knapp KM; Leukemia Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alonzo TA; Children's Oncology Group, Monrovia, CA, USA.
  • Meshinchi S; Department of Biostatistics, University of Southern California, Los Angeles, CA, USA.
  • Stone RM; Children's Oncology Group, Monrovia, CA, USA.
  • Kornblau SM; Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA, USA.
  • Marcucci G; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gamis AS; Department of Leukemia, The University of Texas and MD Anderson Cancer Center, Houston, TX, USA.
  • Byrd JC; Gehr Family Leukemia Center, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Gonen M; Children's Oncology Group, Monrovia, CA, USA.
  • Levine RL; Division of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA.
  • Kentsis A; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Br J Haematol ; 176(1): 86-91, 2017 Jan.
Article in En | MEDLINE | ID: mdl-27766616
Cure rates of children and adults with acute myeloid leukaemia (AML) remain unsatisfactory partly due to chemotherapy resistance. We investigated the genetic basis of AML in 107 primary cases by sequencing 670 genes mutated in haematological malignancies. SETBP1, ASXL1 and RELN mutations were significantly associated with primary chemoresistance. We identified genomic alterations not previously described in AML, together with distinct genes that were significantly overexpressed in therapy-resistant AML. Defined gene mutations were sufficient to explain primary induction failure in only a minority of cases. Thus, additional genetic or molecular mechanisms must cause primary chemoresistance in paediatric and adult AML.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Drug Resistance, Neoplasm / Genomics Type of study: Prognostic_studies Limits: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Br J Haematol Year: 2017 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Drug Resistance, Neoplasm / Genomics Type of study: Prognostic_studies Limits: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Br J Haematol Year: 2017 Type: Article Affiliation country: United States